Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jaime Bosch

Showing results (341-350 of 364) with videos related to

Pageof 37
Sort By:
The American Journal of Gastroenterology|May 13, 2021
Noninvasive Diagnosis of Portal Hypertension in Patients With Compensated Advanced Chronic Liver DiseaseMonica Pons, Salvador Augustin, Bernhard Scheiner, et al.
Hepatology (Baltimore, Md.)|April 18, 2019
The Natural History of Advanced Fibrosis Due to Nonalcoholic Steatohepatitis: Data From the Simtuzumab TrialsArun J Sanyal, Stephen A Harrison, Vlad Ratziu, et al.
British Journal of Clinical Pharmacology|December 9, 2025
Effects of zibotentan and dapagliflozin combined in patients with compensated cirrhosis: A randomized placebo-controlled exploratory studyJuan Carlos Garcia-Pagan, Lise Lotte Gluud, Mattias Mandorfer, et al.
Cancers|June 2, 2021
Transcriptomic Profiling of the Liver Sinusoidal Endothelium during Cirrhosis Reveals Stage-Specific Secretory SignatureNicolò Manicardi, Anabel Fernández-Iglesias, Laia Abad-Jordà, et al.
Hepatology (Baltimore, Md.)|October 18, 2021
Cirrhosis regression is associated with improved clinical outcomes in patients with nonalcoholic steatohepatitisArun J Sanyal, Quentin M Anstee, Michael Trauner, et al.
Journal of Hepatology|September 4, 2022
Incidence and factors predictive of recurrent thrombosis in people with non-cirrhotic portal vein thrombosisAnna Baiges, Bogdan Procopet, Gilberto Silva-Junior, et al.
Hepatology (Baltimore, Md.)|August 1, 2021
A Machine Learning Approach to Liver Histological Evaluation Predicts Clinically Significant Portal Hypertension in NASH CirrhosisJaime Bosch, Chuhan Chung, Oscar M Carrasco-Zevallos, et al.
JHEP Reports : Innovation in Hepatology|October 29, 2021
Serum miR-181b-5p predicts ascites onset in patients with compensated cirrhosisAna Garcia Garcia de Paredes, Càndid Villanueva, Carolina Blanco, et al.
Gastroenterology|July 11, 2018
Simtuzumab Is Ineffective for Patients With Bridging Fibrosis or Compensated Cirrhosis Caused by Nonalcoholic SteatohepatitisStephen A Harrison, Manal F Abdelmalek, Stephen Caldwell, et al.
Gut|February 7, 2023
Liver stiffness thresholds to predict disease progression and clinical outcomes in bridging fibrosis and cirrhosisRohit Loomba, Daniel Q Huang, Arun J Sanyal, et al.
Pageof 37

Showing results (341-350 of 364) with videos related to

Sort By:
Pageof 37
The American Journal of Gastroenterology|May 13, 2021
Noninvasive Diagnosis of Portal Hypertension in Patients With Compensated Advanced Chronic Liver DiseaseMonica Pons, Salvador Augustin, Bernhard Scheiner, et al.
Hepatology (Baltimore, Md.)|April 18, 2019
The Natural History of Advanced Fibrosis Due to Nonalcoholic Steatohepatitis: Data From the Simtuzumab TrialsArun J Sanyal, Stephen A Harrison, Vlad Ratziu, et al.
British Journal of Clinical Pharmacology|December 9, 2025
Effects of zibotentan and dapagliflozin combined in patients with compensated cirrhosis: A randomized placebo-controlled exploratory studyJuan Carlos Garcia-Pagan, Lise Lotte Gluud, Mattias Mandorfer, et al.
Cancers|June 2, 2021
Transcriptomic Profiling of the Liver Sinusoidal Endothelium during Cirrhosis Reveals Stage-Specific Secretory SignatureNicolò Manicardi, Anabel Fernández-Iglesias, Laia Abad-Jordà, et al.
Hepatology (Baltimore, Md.)|October 18, 2021
Cirrhosis regression is associated with improved clinical outcomes in patients with nonalcoholic steatohepatitisArun J Sanyal, Quentin M Anstee, Michael Trauner, et al.
Journal of Hepatology|September 4, 2022
Incidence and factors predictive of recurrent thrombosis in people with non-cirrhotic portal vein thrombosisAnna Baiges, Bogdan Procopet, Gilberto Silva-Junior, et al.
Hepatology (Baltimore, Md.)|August 1, 2021
A Machine Learning Approach to Liver Histological Evaluation Predicts Clinically Significant Portal Hypertension in NASH CirrhosisJaime Bosch, Chuhan Chung, Oscar M Carrasco-Zevallos, et al.
JHEP Reports : Innovation in Hepatology|October 29, 2021
Serum miR-181b-5p predicts ascites onset in patients with compensated cirrhosisAna Garcia Garcia de Paredes, Càndid Villanueva, Carolina Blanco, et al.
Gastroenterology|July 11, 2018
Simtuzumab Is Ineffective for Patients With Bridging Fibrosis or Compensated Cirrhosis Caused by Nonalcoholic SteatohepatitisStephen A Harrison, Manal F Abdelmalek, Stephen Caldwell, et al.
Gut|February 7, 2023
Liver stiffness thresholds to predict disease progression and clinical outcomes in bridging fibrosis and cirrhosisRohit Loomba, Daniel Q Huang, Arun J Sanyal, et al.
Pageof 37